Morgan Stanley Keeps Equal-Weight Rating, PT Raised to $86 from $75

Morgan Stanley Keeps Equal-Weight Rating, PT Raised to $86 from $75

Morgan Stanley has maintained its Equal-Weight rating on Nutrien (NYSE:NTR) but increased its price target from $75 to $86. This update comes ahead of Nutrien's second-quarter 2025 earnings report, scheduled for August 6. The investment bank has revised its second-quarter 2025 EBITDA estimate downward from $2,567 million to $2,399 million, still above the consensus estimate of $2,297 million. Similarly, the second-quarter earnings per share projection was adjusted from $2.79 to $2.53, exceeding the consensus of $2.37. Despite these revisions, Morgan Stanley's full-year 2025 EBITDA forecast remains above the consensus estimate of $5,683 million, with the EPS estimate slightly reduced from $4.41 to $4.34.

Nutrien's stock has delivered an impressive 38.93% return year-to-date and is currently trading near its 52-week high of $65.08. The company has demonstrated consistent shareholder returns, having raised its dividend for seven consecutive years. Nutrien's market capitalization stands at $29.71 billion, with a current dividend yield of 3.58%.

Morgan Stanley noted that most analysts have not yet updated their models for the upcoming quarterly report. The company maintains strong financial health metrics, with management actively buying back shares. For deeper insights into Nutrien's valuation and growth prospects, investors can access the comprehensive Pro Research Report available exclusively on InvestingPro.

In other recent news, RBC Capital Markets raised its price target for Nutrien to $65, maintaining an Outperform rating. BofA Securities also increased its price target for Nutrien to $63, reaffirming a Buy rating based on the company's potential for growth in the potash market. However, Jefferies downgraded Nutrien from Buy to Hold, expressing concerns about long-term supply shocks and potential margin pressures. Similarly, Raymond James downgraded Nutrien to Market Perform, noting recent share price gains and a potential decoupling from corn prices.

These recent developments highlight varied analyst perspectives on Nutrien's future performance amidst fluctuating market conditions.

References:
[1] https://www.investing.com/news/analyst-ratings/morgan-stanley-reiterates-equalweight-rating-on-nutrien-stock-at-65-93CH-4135748
[2] https://www.gurufocus.com/news/2969603/morgan-stanley-boosts-synchrony-syf-price-target-to-70-syf-stock-news
[3] https://ng.investing.com/news/analyst-ratings/morgan-stanley-reiterates-overweight-rating-on-rhythm-pharmaceuticals-stock-93CH-2001409